ReviewCurrent pharmaceutical design2008
Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.
Review in Current pharmaceutical design, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 75 citations in OpenAlex.
- Zero-Background Small-Molecule Sensors for Near-IR Fluorescent Imaging of Biomacromolecular Targets in Cells.ACS sensors · 2023Article
- Radioimmunoimaging ofOncology letters · 2019Article
- Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody-Labeled Near-Infrared Fluorophore.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Synthesis and evaluation ofChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- Imaging EGFR and HER3 throughScientific reports · 2018Article
- Mapping Sentinel Lymph Node Metastasis by Dual-probe Optical Imaging.Theranostics · 2017Article
- Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.Pharmaceutical patent analyst · 2016Review
- Radiopharmaceuticals as probes to characterize tumour tissue.European journal of nuclear medicine and molecular imaging · 2015Review
- Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging.Frontiers in pharmacology · 2014Article
- Positron emission tomography-computed tomography in the management of lung cancer: An update.South Asian journal of cancer · 2013Review
- Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Pharmacological reviews · 2013Review
- Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.American journal of nuclear medicine and molecular imaging · 2013Article
- The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma.Mediators of inflammation · 2013Article
- A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies.EJNMMI research · 2012Article
- Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.Cancer science · 2012Article
- Whole-body biodistribution kinetics, metabolism, and radiation dosimetry estimates of 18F-PEG6-IPQA in nonhuman primates.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011Article
- Assessment of tumor response to tyrosine kinase inhibitors.Frontiers in bioscience (Landmark edition) · 2011Review
- Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes.Bioorganic & medicinal chemistry · 2011Article
- Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription.Seminars in radiation oncology · 2011Review
- Current molecular imaging positron emitting radiotracers in oncology.Nuclear medicine and molecular imaging · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein tyrosine kinases (PTKs) play a pivotal role in signal transduction pathways and in the development and maintenance of various cancers. They are involved in multiple processes such as transcription, cell cycle progression, proliferation, angiogenesis and inhibition of apoptosis. Among the PTKs, the EGFR is one of the most widely studied and has emerged as a promising key target for the treatment of cancer. Indeed, several drugs directed at this receptor are FDA-approved and many others are at various stages of development. However, thus far, the therapeutic outcome of EGFR-targeted therapy is suboptimal and needs to be refined. Quantitative PET molecular imaging coupled with selective labelled biomarkers may facilitate in vivo EGFR-targeted drug efficacy by noninvasively assessing the expression of EGFR in tumor, guiding dose and regime by measuring target drug binding and receptor occupancy as well as potentially detecting the existence of a primary or secondary mutation leading to either drug interaction or failure of EGFR recognition by the drug. This review describes the attempts to develop labelled EGFR molecular imaging agents that are based either on low molecular weight tyrosine kinase inhibitors or monoclonal antibodies directed to the extracellular binding domain of the receptor to be used in nuclear medicine modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.